UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On March 10, 2023, Talaris Therapeutics, Inc. (the "Company") confirmed that it does not hold cash deposits or securities at Silicon Valley Bank.
The information contained in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements of the Company that involve substantial risks and uncertainties. Any statements in this Form 8-K about the Company's expectations constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company. In this Form 8-K, the Company's forward looking statements include statements about its exposure to Silicon Valley Bank. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the effect of and uncertainties related to macroeconomic factors such as inflation, rising interest rates and any impact or deterioration in the banking industry and credit markets, including related to the closure of Silicon Valley Bank, and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
TALARIS THERAPEUTICS, INC. |
|
|
|
|
Date: |
March 10, 2023 |
By: |
/s/ Scott Requadt |
|
|
Name: Title: |
Scott Requadt |
Document And Entity Information |
Mar. 10, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 10, 2023 |
Entity Registrant Name | TALARIS THERAPEUTICS, INC. |
Entity Central Index Key | 0001827506 |
Entity Emerging Growth Company | true |
Securities Act File Number | 001-40384 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 83-2377352 |
Entity Address, Address Line One | 93 Worcester St. |
Entity Address, City or Town | Wellesley |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02481 |
City Area Code | 502 |
Local Phone Number | 398-9250 |
Entity Information, Former Legal or Registered Name | Not Applicable |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Ex Transition Period | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | TALS |
Security Exchange Name | NASDAQ |
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end
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
=C/75JH#>$:0R4@^)/_?X#$IBNA!V M>7*"41_//SY[Q(U;4H\543L&79P8'LRZVC1:A1-1Q&F__>)T_L:EP6NX]NP% MWVQDJH!6,6Z/WNYMOR/WJ7K2SXSBZU[QX;C@LT%8D2?1GNG/*=NF.E,IPJ); M>S::*+I#$R$Q5MN&8]N.K6M^$:9$VB?;AFN0A4(R(M*T#QW@_R1I_YZ^5>0T M:ZNHY+*?+Y9;>VGK0D&NR*ZMHA/5AES>S<\A;[=*D0?:3[)V!_6-7%]]H^UT M62176-_-OZ26DD?>= ?6?6_9+?OD:_:IYJK.U(UR MH9]K+_1M5:9\*ZU[.!Z6HO*UK&\^?::.E4O\O;82CVM?N4O6]P@\7SS+5=8W MQ3Y5; W\RSN,JW5=:L;]05E0AS/ZSOD7Y08 U:=!_]'^:W?T'4$L! A0#% @ 8(!J5L].\&@$ M%0 VLP !$ ( ! '1A;',M,C R,S S,3 N:'1M4$L! M A0#% @ 8(!J5J06$? / P FPD !$ ( !,Q4 '1A M;',M,C R,S S,3 N>'-D4$L! A0#% @ 8(!J5@[;FP$"!@ P38 !4 M ( !<1@ '1A;',M,C R,S S,3!?;&%B+GAM;%!+ 0(4 Q0 M ( &" :E;Q@..>P00 "@H 5 " :8> !T86QS+3(P D,C,P,S$P7W!R92YX;6Q02P4& 0 ! $ 0 FB, end